Recent developments in the pharmacological treatment of Crohn’s disease

@article{Srinivasan2004RecentDI,
  title={Recent developments in the pharmacological treatment of Crohn’s disease},
  author={R. Srinivasan and G. Lichtenstein},
  journal={Expert Opinion on Investigational Drugs},
  year={2004},
  volume={13},
  pages={373 - 391}
}
Therapy for Crohn’s disease (CD) is rapidly evolving with the emergence of new discoveries in disease pathogenesis. Since the approval of the first biological agent, infliximab, there have been several others that have been studied and are available for use within the context of clinical trials, in CD patients who do not respond to conventional medications or whose disease cannot be maintained in remission with the use of infliximab. The number of available drugs that have focused on the… Expand
Advances in gastrointestinal pharmacotherapy.
Medical Management of Crohn's Disease in 2006: What's on the Horizon?
Phthaloyl amino acids as anti-inflammatory and immunomodulatory prototypes
Traveller's diarrhoea.
...
1
2
...

References

SHOWING 1-10 OF 139 REFERENCES
Leflunomide Treatment of Crohn's Disease Patients Intolerant to Standard Immunomodulator Therapy
Natalizumab for active Crohn's disease.
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
...
1
2
3
4
5
...